Loading stock data…
Cencora, Inc. (COR)
$330.95-6.27 (-1.86%)
Pre-Market$329.10-1.85 (-0.56%)· Last close Sep 4
Cencora, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cencora, Inc. in the Healthcare sector is trading at $330.95 with a market capitalization of $63.2B. Wall Street consensus targets $369.31 (13 analysts), implying a +11.6% move over the next 12 months. The stock is currently 12% below its 52-week high of $377.54, remaining 3.2% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $84.75B↑ | $78.36B↓ | $85.93B↑ | $83.73B↑ | $80.66B |
| Gross Profit | $3.61B↑ | $3.59B↑ | $3.07B↑ | $2.95B↑ | $2.91B |
| Operating Income | $1.21B↓ | $1.36B↑ | $1.02B↑ | $945.94M↓ | $980.24M |
| Net Income | $763.52M↓ | $1.64B↑ | $559.65M↑ | -$339.70M↓ | $687.40M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home hea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$63.15B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.57
Beta
Defensive asset. Lower volatility than the S&P 500.
0.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.73%
ROE
Elite ROE. Management converts capital into profit efficiently.
86.03%
Volume
Today's trading volume
1.02M
Recent News
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Is Cencora (COR) Still Undervalued On Higher 2026 Guidance And Strong Q3 Earnings?
Cencora (COR) drew investor attention after third quarter results showed adjusted earnings per share of US$4.48, up 12% year over year, along with a higher fiscal 2026 adjusted earnings outlook. Cencora's latest earnings beat and higher 2026 guidance come after a strong run, with the share price up 22.6% over 90 days and a 1 year total shareholder return of 16.1%, building on a 5 year total shareholder return of 186.8%. Capitalize on Cencora's earnings momentum by scanning a hand picked group...